Anton Gueth Net Worth

The estimated Net Worth of Anton Gueth is at least 854 千$ dollars as of 8 July 2021. Anton Gueth owns over 100,000 units of Navidea Biopharmaceuticals Inc stock worth over 468$ and over the last 13 years Anton sold NAVB stock worth over 853,750$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anton Gueth NAVB stock SEC Form 4 insiders trading

Anton has made over 10 trades of the Navidea Biopharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Anton sold 100,000 units of NAVB stock worth 429,000$ on 8 July 2021.

The largest trade Anton's ever made was selling 100,000 units of Navidea Biopharmaceuticals Inc stock on 8 July 2021 worth over 429,000$. On average, Anton trades about 18,340 units every 123 days since 2012. As of 8 July 2021 Anton still owns at least 467,577 units of Navidea Biopharmaceuticals Inc stock.

You can see the complete history of Anton Gueth stock trades at the bottom of the page.

What's Anton Gueth's mailing address?

Anton's mailing address filed with the SEC is C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300, EWING, NJ, 08628.

Insiders trading at Navidea Biopharmaceuticals Inc

Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over 3,167,813$ worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth 6,241,151$ . The most active insiders traders include John K Jr. Scott、Perry A Karsen、Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of 159$. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth 3$.

What does Navidea Biopharmaceuticals Inc do?

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Complete history of Anton Gueth stock trades at Antares Pharma Inc、Spectrum Pharmaceuticals、Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc executives and stock owners

Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jed Latkin,
  Chief Executive Officer, Chief Financial Officer, Chief Operating Officer
• Dr. Michael Stanley Rosol Ph.D.,
  Sr. VP & Chief Medical Officer
• Michael Rosol,
  Chief Medical Officer
• Y. Michael Rice,
  Independent Chairman of the Board
• S. Kathryn Rouan,
  Independent Director
• Adam Cutler,
  Independent Director
• Claudine Bruck,
  Independent Director
• Dr. Michel Mikhail Ph.D.,
  Chief Regulatory Officer
• Jeffrey Smith,
  VP of Operations
• Joel Harrison Kaufman,
  Chief Bus. Officer
• William J. Regan,
  Chief Strategy Officer & Chief Compliance Officer
• Erika Gibson,
  Director of Fin. & Admin.
• Alexander L Cappello,
  Director
• Anthony S. Fiorino,
  Director
• Mark I Greene,
  Director
• Brent L Larson,
  EVP, CFO, Treas and Secy
• Gordon A Troup,
  Director
• Eric K Rowinsky,
  Director
• Thomas J Klima,
  SVP & Chief Commercial Ofc
• William J. Regan,
  SVP-Global Regulatory Strategy
• Michael M Goldberg,
  Director
• Frederick O Cope,
  Senior VP and CSO
• John K Jr. Scott,
  
• Life Sciences, Llc Platinum...,
  
• Rodger A Brown,
  Vice President
• Perry A Karsen,
  Director
• Thomas H. Tulip,
  President
• Mark Platinum Management (N...,
  
• Brendan A Ford,
  Director
• Mark Jerome Pykett,
  Pres. & CEO
• Cornelia Reininger,
  SVP & Chief Medical Officer
• Jess Jones,
  Director
• Anton Gueth,
  Director
• Dana J Moss,
  
• Joel H. Kaufman,
  Chief Business Officer
• Malcolm G Witter,
  Director
• Amit Bhalla,
  Director
• Michel Mikhail,
  Chief Regulatory Officer
• Agnieszka Winkler,
  Director
• Thomas F Farb,
  Director
• Joshua M. Wilson,
  Director
• Jill Stefanelli,
  
• Craig Dais,
  CHIEF FINANCIAL OFFICER